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Abstract
Background: Human infection with influenza A(H1N1) 2009 was first identified in the United States on 15 April
2009 and on 11 June 2009, WHO declared that the rapidly spreading swine-origin influenza virus constituted a
global pandemic. We evaluated the seroprevalence of influenza A(H1N1) 2009 virus on a large public University
campus, as well as disparities in demographic, symptomatic and vaccination characteristics of participants.
Methods: Using a cross-sectional study design, sera was collected from volunteers and then tested for the
presence of antibodies to the virus using a ≥ 1:40 dilution cut-off by hemagglutination inhibition assay. In
conjunction, participants were asked to complete a questionnaire allowing us to estimate risk factors for infection
in this population, as well as distinguish artificially derived antibodies from naturally derived antibodies.
Results: 300 total participants were recruited and tested. 158 (52.6%) tested positive for influenza A(H1N1) 2009 via
hemagglutination inhibition assay using a ≥ 1:40 dilution cut-off. 86 people (54.4%) tested positive for H1N1 but
did not report experiencing symptoms during the pandemic meeting the May 2010 CDC definition of influenza-
like illness. Furthermore, of those individuals who reported that they had received the H1N1 vaccine, 16% did not
test positive.
Conclusions: Overall, 52.7% of the total study population tested positive for influenza A(H1N1) 2009. 54.4% of
those who tested positive for influenza A(H1N1) 2009 using the ≥ 1:40 dilution cut-off on the hemagglutination
inhibition assay in this study population did not report experiencing symptoms during the pandemic meeting the
May 2010 CDC definition of influenza-like illness. 16% of those who reported receiving the H1N1 vaccine did not
test positive by HAI. We also found that vaccination coverage for H1N1 vaccine was poor among Blacks and
Latinos, despite the fact that vaccine was readily available at no cost.
Background
Human infection with influenza A(H1N1) 2009 was first
identified in the United States on 15 April 2009 and on
11 June 2009, WHO declared that the rapidly spreading
swine-origin influenza virus constituted a global pan-
demic [1]. Influenza A(H1N1) 2009 is characterized by a
combination of gene segments not previously identified
[2]. Within weeks of the beginning of the epidemic,
public health laboratories quickly became overwhelmed
with unprecedented numbers of clinical influenza speci-
mens for testing, and the Centers for Disease Control
and Prevention (CDC) quickly recommended changes in
the testing strategy [3]. The CDC recommended that
since uncomplicated influenza did not require a labora-
tory diagnosis for clinical management, the only people
who required testing for influenza were: hospitalized
patients with suspected influenza, patients for whom a
diagnosis of influenza would have informed decisions
regarding clinical care, infection control, or management
of close contacts, and patients who died of an acute ill-
ness in which influenza was suspected.
According to the CDC, diagnosis of other groups was
not considered a priority for a number of reasons, the
foremost of which being “Once influenza activity has
been documented in a community or geographic area,
most patients with an uncomplicated illness consistent
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with influenza can be diagnosed clinically and do not
require influenza testing for clinical management,
including antiviral treatment decisions [4].”
While this strategy was extremely prudent with
respect to management of the resources of public health
laboratories and the ability to clinically manage influ-
enza A(H1N1) 2009 cases, in the absence of serological
surveys of the population it is not possible to accurately
measure the critical demographic, symptomatic and vac-
cination characteristics of the influenza A(H1N1) 2009
virus.
After the beginning of the global pandemic, several
national representative serosurveys were conducted in
order to get a picture of the population immunity pro-
file as well as to get a picture of the infection during the
first wave [5-7]. Serosurveys were also conducted among
a variety of targeted populations in different regions
throughout the world throughout the course of the pan-
demic [8-13]. To our knowledge, however, our study
represents the first targeted serosurvey conducted
among the high risk population of college-age students
on a University campus. These results should allow for
evidence-based decisions during future waves and
potentially during future epidemics.
Methods
Approval for this study was obtained from Medical IRB-
2 at UCLA. Written consent was obtained from all
participants.
Participants were recruited for participation via conve-
nience sampling on the UCLA campus. Anyone who
fulfilled the inclusion criteria (at least 18 years of age,
able to give informed consent in English and affiliated
with the UCLA community) was offered enrollment in
the study. Potential participants were recruited from
large gatherings of UCLA students, faculty and staff in
order to maximize participation in the study. Following
the process of informed consent, all participants com-
pleted a comprehensive questionnaire containing ques-
tions about their basic demographic information
including their date of birth, gender, race, location of
residence (on/off campus), and affiliation with UCLA
(undergraduate, graduate, faculty, staff or other). The
questionnaire also inquired about their vaccination sta-
tus (both seasonal and H1N1 vaccine) and history of
flu-like symptoms including chills, cough, diarrhea,
fever, headache, muscle aches, nausea, runny nose, sore
throat, stuffy nose and vomiting. They were asked
whether or not they sought medical care, whether or
not they had been diagnosed with H1N1 and whether
or not they had been hospitalized due to H1N1 infec-
tion. They were also asked whether or not they had
known exposures to individuals who had been diagnosed
with H1N1 infection. In order to attempt to minimize
recall bias, for each question participants were specifi-
cally prompted to think about the time frame from
April 2009 until the current date (May 2010). All sub-
jects were recruited in May of 2010.
A 10 ml venous blood sample was then collected from
all willing participants. Participants were free at any
point to decline to give detailed information and/or bio-
logical specimens and they were free to end their parti-
cipation in the study at anytime. In total, 300
participants were enrolled in the study.
Blood specimens were centrifuged and separated into
plasma and buffy-coat aliquots prior to being frozen and
stored in a - 20°C freezer at UCLA until they were
ready for laboratory analysis at the University of Florida.
Antibody responses were detected by use of a routine
standard Centers for Disease Control and Prevention
protocol hemagglutination antibody inhibition (HAI)
analysis to detect antibodies to influenza A(H1N1) 2009
(A/Mexico/4108/09(pandemic H1N1)). The human
H1N1 strain was grown in MDCK cells. Serum samples
were pretreated with receptor-destroying enzymes (1
part serum to 3 parts enzyme) from Vibrio cholerae
overnight, and then were hemadsorbed with guinea pig
blood. Serial two-fold dilutions of serum were tested
beginning with a 1:10 dilution and a final dilution of
1:640. Suitable control samples were included in all
assays. HI titer results were reported as the reciprocal of
the highest dilution of serum that inhibited virus-
induced hemagglutination of a 0.5% (from guinea pigs)
solution of erythrocytes [14,15]. In order to be consis-
tent with other published papers in the field, sera were
considered positive at an HI titre of 1: 40 or greater
since titres greater than 1: 40 are correlated with a
reduction of 50% of the risk of contracting an influenza
infection [16-23]. While the authors acknowledge this is
a highly sensitive threshold, it may come at the compro-
mise of specificity.
Analyses were conducted using the SAS software
(SAS, Inc., V.9.1). A cross-sectional analysis was per-
formed using the questionnaire data obtained from the
participants. Descriptive variables were examined and
then we cross-tabulated variables of interest to explore
any apparent associations. When analyzing sympto-
matic characteristics, we looked at which participants
reported the aggregate of symptoms which met the
May 2010 CDC definition on influenza-like illness
(fever AND cough and/or sore throat). Because of
small sample size, more complex statistical analyses
were not performed.
Results and discussion
A total of 300 subjects were recruited into the study.
The characteristics of study participants are presented
in Table 1.
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185 (61.7%) were female and 115 (38.3%) were male.
227 (75.7%) were UCLA undergraduate students, 42
(14.0%) were graduate students, 1(.3%) was a faculty
member and 15 (5%) were classified as “other.” 146
(48.7%) were White, non-Latino, 93 (31.0%) participants
were Asian/Pacific Islander, 36 (12.0%) identified as
Latino, 14 (4.7%) identified as Black, Non-Latino, 6
(2.0%) identified as Mixed race, 2 (.7%) individuals were
Native American, and 3 (1.0%) individuals declined to
specify. 81 (27%) reported that they had a known expo-
sure to an individual with H1N1. 187 (62.3%) reported
that they had had flu-like symptoms since the beginning
of the previous season. Only 112 (37.3%), however, met
the May 2010 CDC definition of influenza-like illness
(fever AND cough and/or sore throat). Of those 112
individuals, only 72 people tested positive for H1N1
using a ≥ 1:40 dilution cut-off by HAI. 86 people
(54.4%) tested positive for H1N1 and did not report
experiencing symptoms meeting the May 2010 CDC
definition of influenza-like illness. Among those who
tested positive for Influenza A(H1N1) 2009, diarrhea
and vomiting were the least commonly reported symp-
toms (18.4% and 10.8% respectively), whereas sore
throat and stuffy nose were the most commonly
reported symptoms (63.3% and 60.8% respectively).
Symptomatic distributions of those individuals who
tested positive for influenza A(H1N1) 2009 are shown
in Table 2.
While 85 (28.3%) participants reported that they had
received “any” flu shot, only 61 (20.3%) of the partici-
pants reported that they had received the H1N1 flu
shot. 8 individuals (2.7%) reported that they had been
previously diagnosed with H1N1 by a health
professional.
Results of the hemagglutination inhibition assay are
shown in Table 3. Demographic characteristics of parti-
cipants both by vaccination and seropositivity status are
reported in Table 4.
Even when using a very sensitive cut-off of ≥ 1:40 for
the HAI results, 10 of 61 (16%) individuals who self-
reported having specifically received the H1N1 vaccine
did not test positive. Demographic and serologic charac-
teristics of those who reported receipt of the 2009
H1N1 vaccine are shown in Table 5, whereas demo-
graphic and serologic characteristics of those who did
not report receipt of the 2009 H1N1vaccine are shown
in Table 6.
Conclusions
Overall, 52.7% of the total study population tested posi-
tive for influenza A(H1N1) 2009. Because of the conve-
nience sampling design, it is unclear if this is
representative of the UCLA population in general or if







Asian/Pacific Islander 93 (31)
Black, Non-Latino 14 (4.6)
Latino 36 (12)
Native American/Alaskan 2 (.66)
White, Non-Latino 146 (48.6)
Mixed 6 (2)
Not Specified 3 (1)
Total 300
Location of Residence
On campus 81 (27)









Table 2 Distribution of symptoms among those who
tested positive for influenza A(H1N1) 2009







Muscle Aches 58 (36.7)
Nausea 35 (22.2)
Runny Nose 93 (58.9)
Sore Throat 100 (63.3)
Stuffy Nose 96 (60.8)
Vomiting 17 (10.8)




*17 of the 49 people (35.0%) who reported experiencing no symptoms also
reported receipt of the 2009 H1N1 vaccine
**Sera were considered positive at an HI titre of 1:40 or greater
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the study population was comprised of highly motivated
participants. Even if it was representative of UCLA, it is
unclear if the results would be generalizable to all uni-
versities in general or even just to all large public uni-
versities. 54.4% of those who tested positive for
influenza A(H1N1) 2009 in this study population, using
the ≥ 1:40 dilution cut-off on the hemagglutination inhi-
bition assay, did not meet the May 2010 CDC definition
for influenza-like illness. Furthermore, 49 (31%) people
who tested positive did not report experiencing any flu-
like symptoms at all. Of those individuals, 32 (65.3%)
also did not report receiving the 2009 H1N1 vaccine,
therefore we believe them to have been truly asympto-
matic cases based on self reporting of symptoms.
Although the potential existed for inaccurate reporting
of symptoms and vaccination given the population of
college students and the long time frame about which
they were asked to recall, the questionnaire was specifi-
cally designed to minimize such bias. This suggests that
either a large number of cases of influenza A(H1N1)
2009 are asymptomatic or subclinical, presenting with
either absent or mild symptoms that were not readily
observable; the 1:40 dilution cut-off on the hemaggluti-
nation inhibition assay had low specificity or there was
poor specificity on the May 2010 CDC case definition.
Since previous serosurveys did indicate high levels of
asymptomatic or subclinical infection, we believe that
many individuals in our population were asymptomati-
cally or subclinically infected as well [5]. If nearly half of
those infected do not mount any symptoms of infection
or symptoms so mild as to avoid detection by the indivi-
dual this represents a special population that may have
both positive and negative impacts on preparedness
efforts. This potentially large asymptomatic or subclini-
cal population would be less likely to engage in isolation
or social distancing measures that have been proven to
be effective given that they are unaware of their infec-
tion and therefore of their ability to transmit the virus
[24]. Additional research regarding such ability of these
asymptomatic individuals to transmit the virus needs to
be done [25,26]. Conversely, if these asymptomatic or
subclinically infected individuals simultaneously mount
a protective immune response to the infection, then
Table 4 Distribution of demographic characteristics by
vaccination and seropositivity status
Characteristics No (% of subgroup)
vaccinated
No (% of subgroup)
seropositive
Gender
Male 28 (24.4) 66 (41.77)





23 (24.7) 58 (62)
Black, Non-
Latino
0 (0) 9 (64)




1 (50) 1 (50)
White, Non-
Latino
31 (21.2) 67 (45.9)
Mixed 1 (16.7) 2 (33.3)
Not Specified 0 (0) 1 (33)
Total 61 (20.3) 158 (52.7)
Table 5 Demographic and serologic characteristics
among those who reported receipt of 2009 H1N1 vaccine






Male 24 (85.7) 3 (10.7)
Female 26 (78.8) 7 (21.2)




19 (82.6) 4 (17.4)
Black, Non-
Latino
0 (0) 0 (0)




1 (100.0) 0 (0)
White, Non-
Latino
25 (80.6) 5 (16.1)
Mixed 0 (0) 1 (100.0)
Not Specified 0 (0) 0 (0)
Total 50 (82.0) 10
*Table does not include those with no results or no sample from HAI,
therefore some percentages might not sum to 100
Table 3 Distribution of 2009 H1N1 hemagglutination
inhibition assay results
H1N1 Lab Results







≤ 640 27 9.0%
No Results 21 7.0%
No Sample 2 0.7%
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fewer people will need to be vaccinated in order to gen-
erate herd immunity to the virus. However, the possibi-
lity must be considered that a 1:40 dilution, which is the
widely used field standard for serosurveys, does not
actually indicate the presence of lasting protective
immunity. Therefore, this seroprevalance data cannot
independently be used to generate conclusions about
herd immunity and must be used in conjunction with
information on the R0 of this virus. Until these critical
issues are resolved it is important that individuals follow
the vaccination guidelines set forth by national and
international health agencies.
Because of the location and timing of the study on
the UCLA campus, any undergraduate or graduate stu-
dent would have been eligible to receive free H1N1
vaccine through the University health service, yet only
20.3% of the total study population reported that they
had chosen to receive the vaccine. We contacted the
University health service and found that the total num-
ber of H1N1 vaccines given out by their office to stu-
dents at UCLA during the period from which they
received the vaccine and began to make it available (19
October 2009 until 3 March 2010) was 1802. Using the
Fall 2009 enrollment information at UCLA as a
denominator, we calculated that the total prevalence of
vaccination on campus was 1802 out of 38556 total
students, or 4.67%. It is our thought that the discre-
pancy in vaccination prevalence between our study and
the total UCLA population was partially due to the
method of vaccine administration. The only vaccine
available on the UCLA campus was injection and, as
we were asking patients to give a blood sample in our
study, we will assume that our study population repre-
sented a highly motivated and non-needle averse group
of individuals. Large differences in vaccination cover-
age were also seen by self-reported race/ethnicity.
None of the individuals who self-identified as black,
reported that they had been vaccinated with the H1N1
vaccine. However, this is consistent with other pre-
viously published studies indicating difficulty in reach-
ing the African-American population in H1N1
vaccination campaigns [27,28]. Lower reported vacci-
nation was also seen in the Latino participants as com-
pared to the overall study population. While females
appear to be more likely to have been infected with
influenza A(H1N1) 2009 (58.23% vs. 41.77%), males
appear to be slightly more likely to have reported
being vaccinated against influenza A(H1N1) 2009
(24.4% vs. 17.8%). 16% of those who reported vaccina-
tion did not test positive through the Hemagglutina-
tion inhibition assay using a ≥ 1:40 dilution cut-off. It
is possible these negative results occurred because of
problems with the shipping or storage of the blood
specimens, or because of problems with the hemagglu-
tination inhibition assay. However, since the positive
and negative controls that were run with the assays all
turned out appropriately, laboratory error is not the
most likely explanation. Since all individuals who were
recruited into the study were young and healthy, it is
unlikely that these results can be explained because of
anergic participants. One possibility is that this was a
result of recall bias and that participants were unable
to appropriately recall if they had received the seasonal
influenza vaccine or the H1N1 vaccine. It is also possi-
ble that some individuals were vaccinated with product
that was sub-standard, or it is possible that for some
individuals, one dose of vaccine was not sufficient to
stimulate protective immunity against influenza A
(H1N1) 2009. Early in the 2009 epidemic, the Food
and Drug Administration’s designation was that all eli-
gible individuals would need to receive two doses of
the H1N1 vaccine [29]. However, clinical trials showed
that one dose of vaccine was highly immunogenic in
adults [30]. Shortly thereafter, they reassessed their
position, and stated that one dose of vaccine against
influenza A(H1N1) 2009 virus would be sufficient for
individuals 10 years of age and older and only those
children 6 months through 9 years of age would need
two doses [31]. Unfortunately, since influenza A
(H1N1) 2009 is now a component of the seasonal
Table 6 Demographic and serologic characteristics
among those who did not report receipt of 2009 H1N1
vaccine






Male 42 (48.3) 38 (43.7)
Female 66 (43.4) 71 (46.7)




39 (55.7) 25 (35.7)
Black, Non-
Latino
9 (64.3) 4 (28.6)




0 (0) 1 (100.0)
White, Non-
Latino
42 (36.5) 63 (54.8)
Mixed 2 (40.0) 3 (60.0)
Not Specified 1 (33.3) 1 (33.3)
Total 108 (45.2) 109
*Table does not include those with no results or no sample from HAI,
therefore some percentages might not sum to 100
**Table includes those who were unsure of receipt of the 2009 H1N1 vaccine
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vaccine, it is not possible to assess the immunogenicity
of the vaccine using the same methodology.
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